Sean Ekins 9/5/23 Sean Ekins 9/5/23

PsychoGenics And Collaborations Pharmaceuticals Awarded a $1M Grant To Use AI Platforms To Design New Drugs For Mental Health Disorders

PsychoGenics Inc. (PsychoGenics) and Collaborations Pharmaceuticals, Inc. (CPI) are pleased to announce that they were awarded a $1million Phase I Small Business Innovation Research (SBIR) grant, to use their combined AI tools to design new drugs for mental health disorders.

Sean Ekins 6/15/23 Sean Ekins 6/15/23

Collaborations Pharmaceuticals Announces Publication Of New Enterovirus-D68 And Coxsackie B5 Inhibitor

A new paper published in Antiviral Research describes a new inhibitor of Enterovirus-D68 and Coxsackie B5.

Sean Ekins 5/27/22 Sean Ekins 5/27/22

Collaborations Pharmaceuticals, Inc. Announces Publication On Generative Molecule Design Software MegaSyn

Raleigh –Collaborations Pharmaceuticals, Inc. announces the publication of a paper detailing their generative molecule design software, MegaSyn.

Sean Ekins 5/25/22 Sean Ekins 5/25/22

Global Collaboration Demonstrates Pyronaridine Is Active Against COVID-19 In An Animal Model

Raleigh – Collaborations Pharmaceuticals, Inc. and international collaborators publish paper on pyronaridine and its protection against infection with SARS-CoV-2.

Sean Ekins 5/23/22 Sean Ekins 5/23/22

Collaborations Pharmaceuticals, Inc. Announces Major Updates To 2022 Pipeline

Collaborations Pharmaceuticals, Inc. (CPI) announced major updates to their drug discovery research and development pipeline aided by machine learning software.